Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feline Leukemia Virus Monoclonal Antibody
- Development stage
- Unknown
- Lead developer
- Elanco
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Feline Leukemia Virus Monoclonal Antibody is a veterinary biologic developed by Elanco (originally Kindred Biosciences) for the treatment of cats infected with Feline Leukemia Virus (FeLV). As the first monoclonal antibody therapy for this indication, it provides a targeted approach to managing FeLV-associated disease. The antibody works by binding to specific viral proteins, typically the gp70 envelope glycoprotein, thereby neutralizing the virus and preventing it from infecting new feline cells. This reduction in viral replication helps to mitigate the clinical signs and progression of the disease. It received conditional approval from the USDA Center for Veterinary Biologics in 2023, specifically for the treatment of FeLV-infected cats to help reduce the clinical signs of the infection.
- Other names
- anti-feline leukemia virus monoclonal antibodiesFeLV mAbanti-FeLV monoclonal antibody
02
Targets
FeLV Env (Feline leukemia virus envelope protein)
Beyond the preview
Go deeper on Feline Leukemia Virus Monoclonal Antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Feline Leukemia Virus Monoclonal Antibody.